Startseite

Kongressberichte & Archiv

Archiv 2017

40th Annual San Antonio Breast Cancer Symposium (SABCS)

Interviews & Brustkrebs Deutschland Round Table & SAKK Roundtable

Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit Prof. Dr. med. Stefan Buchholz, Regensburg

Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit

Prof. Dr. med. Stefan Buchholz, Regensburg – Thema: Metastasierter Brustkrebs: Umsetzung der Leitlinien und Hormonrezeptor positiver Brustkrebs - Therapieoptionen

News

New Standard of Care: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

03-04-2021 08:40
Weiterlesen ...
Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer

26-03-2021 09:58
Go to the ELCC/ESMO 2021 PRESS RELEASE
SECOND DRUG TARGETING KRAS G12C SHOWS BENEFIT IN MUTATED NON-SMALL-CELL LUNG CANCER

25-03-2021 17:15
Go to the ELCC/ESMO 2021 PRESS RELEASE
ASCO Remembers Breast Cancer Drug Development Pioneer Dr. José Baselga

24-03-2021 09:47
ASCO and the oncology community are deeply saddened by the passing of José Baselga, MD, PhD, FASCO, on March 21, 2021, at age 61. Dr. Baselga died of Creutzfeldt-Jakob disease, a rare fatal neurodegenerative disorder, according to his family. READ MORE
Pembrolizumab + Lenvatinib Significantly Improved PFS & OS vs CT in Advanced Endometrial Cancer Following Prior Platinum-Based CT

22-03-2021 11:06
Read more
Rucaparib Significantly Improves PFS vs Chemotherapy in Later-line Ovarian Cancer with BRCA Mutation

22-03-2021 10:58
Read more
News From the Food and Drug Administration

17-03-2021 12:24
CAR-T Therapy Is Approved for Non-Hodgkin Lymphoma
Weiterlesen ...
HOPOS – Erster nationaler Dachverband in der Schweiz/première organisation faîtière de Suisse

01-03-2021 18:14
«Wir wollen den Hämato-Onkologischen Patienten eine Stimme geben»

« Nous voulons donner une voix aux patients d’hémato-oncologie »
Weiterlesen ...
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma

08-02-2021 10:02
Breyanzi demonstrated a 73% overall response rate and 54% complete response (CR) rate in the largest pivotal trial in 3L+ LBCL, TRANSCEND NHL 001 trial MORE INFO

Renate Haidinger, Brustkrebs Deutschland e.v. im Interview mit

Prof. Dr. med. Stefan Buchholz, Regensburg – Thema: Metastasierter Brustkrebs: Umsetzung der Leitlinien und Hormonrezeptor positiver Brustkrebs - Therapieoptionen

News

New Standard of Care: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer

SECOND DRUG TARGETING KRAS G12C SHOWS BENEFIT IN MUTATED NON-SMALL-CELL LUNG CANCER

ASCO Remembers Breast Cancer Drug Development Pioneer Dr. José Baselga

Pembrolizumab + Lenvatinib Significantly Improved PFS & OS vs CT in Advanced Endometrial Cancer Following Prior Platinum-Based CT

Rucaparib Significantly Improves PFS vs Chemotherapy in Later-line Ovarian Cancer with BRCA Mutation

News From the Food and Drug Administration

HOPOS – Erster nationaler Dachverband in der Schweiz/première organisation faîtière de Suisse

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma

Newsletter